Dec. 15, 2011—The progression of new drug candidates for schizophrenia with partner Janssen Pharmaceutica is the latest evidence that a new collaborative model for drug discovery pioneered at Vanderbilt may help identify and develop innovative candidate drugs for treatment of major brain disorders.
Oct. 31, 2011—A study using a procedure called the rubber hand illusion has found striking new evidence that people experiencing schizophrenia have a weakened sense of body ownership and has produced the first case of a spontaneous, out-of-body experience in the laboratory.
Oct. 3, 2011—Researchers at Vanderbilt University Medical Center have made substantial progress in developing potential new treatments for Parkinson’s disease, schizophrenia and fragile X syndrome, the most common genetic form of autism.
Sep. 22, 2011—The discovery of new compounds that work in a fundamentally different way than those in existing schizophrenia medications may allow for more normal function of brain cells involved in schizophrenia.
May. 24, 2011—Impairments in a brain area involved in social perception may help explain why individuals with schizophrenia have trouble reading social cues.
Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.
Jan. 28, 2011—Individuals with schizophrenia are better at some cognitive tasks than average people, new research from Vanderbilt University indicates. The findings open the door for potential new therapies for these individuals. “We found a pocket of spared or enhanced ability in patients with schizophrenia when almost everything else is impaired,” Vanderbilt psychologist Sohee Park, co-author of...
Jan. 27, 2011—Bringing a new drug to market is an increasingly daunting – and expensive – task. Today it costs more than $1 billion and takes more than seven years, on average, to complete the human studies required for a drug to be approved for marketing. Only about one in five drugs makes it through the clinical...